Eni
Eni optimizes its oil fields with AVEVA PI System
Eni operates in a highly volatile oil and gas market, where long-term performance depends both on optimizing a network of upstream assets and on identifying new extraction opportunities. The group lacked real-time data, which prevented any robust modeling, while data collection, extraction and analysis took considerable time. Deploying AVEVA PI System, along with AVEVA PI Vision and AVEVA PI Server, made it possible to build a true digital oilfield. Data now feeds simulation models representing actual site conditions in real time, paving the way for continuous optimization of asset parameters and maximized production. Field teams can monitor their facilities remotely and receive very early notifications as soon as a problem arises, significantly strengthening Eni's operational responsiveness across its upstream portfolio.
FAQ
How does AVEVA MES ensure GxP traceability in pharmaceuticals?
AVEVA MES structures and digitizes all pharmaceutical production processes in line with GxP (Good Practice) requirements. Every manufacturing step, raw material, operator and piece of equipment used is traced electronically. This granular traceability facilitates regulatory audits (FDA, EMA), speeds up batch release and ensures the regulatory compliance required to bring medicines to market.
Why replace paper with an MES in a pharmaceutical plant?
Paper batch records are slow, error-prone and costly to archive. AVEVA MES digitizes these batch records, automates data collection and applies business rules in real time (checks, electronic signatures, alarms). For a biopharmaceutical manufacturer, this means a drastic reduction in data entry errors, faster batch release and better use of historical data for continuous process improvement.
How does AVEVA accelerate time-to-market for medicines?
AVEVA MES shortens the cycle time between producing a batch and releasing it by automating quality checks, record reviews and signature workflows. For a critical medicine, gaining several days on time-to-market is a major health and financial issue. Process standardization also makes it possible to transfer production from one site to another more quickly, which is essential for responding to demand peaks or shortages.
What role does industrial monitoring play in bioproduction?
Bioproduction (vaccines, antibodies, cell therapies) depends on rigorous control of sensitive biological parameters: temperature, pH, dissolved oxygen and agitation. AVEVA System Platform and InTouch HMI provide real-time industrial monitoring that can immediately detect any drift and protect batch integrity. In this field, quality cannot simply be checked after the fact: it must be built in throughout the process through flawless monitoring.
How does AVEVA support FDA and EMA compliance?
AVEVA life sciences solutions are designed to meet the requirements of regulatory authorities (FDA 21 CFR Part 11, EMA Annex 11): complete audit trails, secure electronic signatures, version management and access control. For a biopharmaceutical manufacturer, this is a strategic asset: regulatory compliance is built into the system from the design stage, reducing risk during inspections and speeding up the registration of new medicines.